HUTCHMED CHINA-ADR (HCM) Stock Price, Forecast & Analysis
NASDAQ:HCM • US44842L1035
HCM Key Statistics, Chart & Performance
The current stock price of HCM is 15.1 USD. In the past month the price decreased by -7.35%. In the past year, price decreased by -7.7%.
HCM Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to HCM. When comparing the yearly performance of all stocks, HCM is a bad performer in the overall market: 68.96% of all stocks are doing better.
HCM Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to HCM. HCM has an average financial health and profitability rating.
HCM Financial Highlights
Over the last trailing twelve months HCM reported a non-GAAP Earnings per Share(EPS) of 2.72. The EPS increased by 1172.34% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 77.53% | ||
| ROA | 26.29% | ||
| ROE | 37.99% | ||
| Debt/Equity | 0.08 |
HCM Forecast & Estimates
24 analysts have analysed HCM and the average price target is 16.17 USD. This implies a price increase of 7.11% is expected in the next year compared to the current price of 15.1.
For the next year, analysts expect an EPS growth of 892.54% and a revenue growth -11.82% for HCM
HCM Ownership
HCM Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 30.41 | 979.461B | ||
| JNJ | JOHNSON & JOHNSON | 21.03 | 586.255B | ||
| MRK | MERCK & CO. INC. | 22.49 | 301.739B | ||
| PFE | PFIZER INC | 9.11 | 155.618B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.82 | 122.858B | ||
| ZTS | ZOETIS INC | 18.8 | 55.333B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.74 | 26.212B | ||
| VTRS | VIATRIS INC | 6.35 | 18.129B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 23.7 | 12.352B | ||
| AXSM | AXSOME THERAPEUTICS INC | 225.58 | 9.24B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About HCM
Company Profile
HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. The company employs 1,780 full-time employees The company went IPO on 2006-05-19. The firm operates its business through two segments. Oncology Immunology segment is engaged in the discovery, development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Among it, research and development (R&D) includes research and development activities covering drug discovery, development, manufacturing and regulatory functions, out-licensing of in-house developed drugs, as well as administrative activities to support research and development operations, marketed products comprises the invoiced sales, marketing, manufacture and distribution of drugs developed from research and development activities. Other Ventures segment is engaged in the other commercial businesses which include the sales, marketing, manufacture and distribution of other prescription drugs and healthcare products.
Company Info
HUTCHMED CHINA-ADR
48th Floor, Cheung Kong Center, 2 Queen's Road Central
Hong Kong HK
CEO: Christian Hogg
Employees: 1780
Phone: 85221281188
HUTCHMED CHINA-ADR / HCM FAQ
Can you describe the business of HUTCHMED CHINA-ADR?
HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. The company employs 1,780 full-time employees The company went IPO on 2006-05-19. The firm operates its business through two segments. Oncology Immunology segment is engaged in the discovery, development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Among it, research and development (R&D) includes research and development activities covering drug discovery, development, manufacturing and regulatory functions, out-licensing of in-house developed drugs, as well as administrative activities to support research and development operations, marketed products comprises the invoiced sales, marketing, manufacture and distribution of drugs developed from research and development activities. Other Ventures segment is engaged in the other commercial businesses which include the sales, marketing, manufacture and distribution of other prescription drugs and healthcare products.
Can you provide the latest stock price for HUTCHMED CHINA-ADR?
The current stock price of HCM is 15.1 USD. The price increased by 1.55% in the last trading session.
What is the dividend status of HUTCHMED CHINA-ADR?
HCM does not pay a dividend.
What is the ChartMill rating of HUTCHMED CHINA-ADR stock?
HCM has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
What do analysts say about HUTCHMED CHINA-ADR (HCM) stock?
24 analysts have analysed HCM and the average price target is 16.17 USD. This implies a price increase of 7.11% is expected in the next year compared to the current price of 15.1.
Is HUTCHMED CHINA-ADR (HCM) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on HCM.
Is HUTCHMED CHINA-ADR (HCM) expected to grow?
The Revenue of HUTCHMED CHINA-ADR (HCM) is expected to decline by -11.82% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.